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Abstract
Background: Sub-microscopic (SM) Plasmodium infections represent transmission reservoirs that could jeopardise malaria
elimination goals. A better understanding of the epidemiology of these infections and factors contributing to their
occurrence will inform effective elimination strategies. While the epidemiology of SM P. falciparum infections has been
documented, that of SM P. vivax infections has not been summarised. The objective of this study is to address this
deficiency.
Methodology/Principal Findings: A systematic search of PubMed was conducted, and results of both light microscopy (LM)
and polymerase chain reaction (PCR)-based diagnostic tests for P. vivax from 44 cross-sectional surveys or screening studies
of clinical malaria suspects were analysed. Analysis revealed that SM P. vivax is prevalent across different geographic areas
with varying transmission intensities. On average, the prevalence of SM P. vivax in cross-sectional surveys was 10.9%,
constituting 67.0% of all P. vivax infections detected by PCR. The relative proportion of SM P. vivax is significantly higher
than that of the sympatric P. falciparum in these settings. A positive relationship exists between PCR and LM P. vivax
prevalence, while there is a negative relationship between the proportion of SM P. vivax and the LM prevalence for P. vivax.
Amongst clinical malaria suspects, however, SM P. vivax was not identified.
Conclusions/Significance: SM P. vivax is prevalent across different geographic areas, particularly areas with relatively low
transmission intensity. Diagnostic tools with sensitivity greater than that of LM are required for detecting these infection
reservoirs. In contrast, SM P. vivax is not prevalent in clinical malaria suspects, supporting the recommended use of quality
LM and rapid diagnostic tests in clinical case management. These findings enable malaria control and elimination programs
to estimate the prevalence and proportion of SM P. vivax infections in their settings, and develop appropriate elimination
strategies to tackle SM P. vivax to interrupt transmission.
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Introduction
The global malaria incidence and death rates have decreased in
recent years [1] due to increasing funding and political commit-
ment, as well as implementation of artemisinin combination
therapy, better access to diagnostics and vector control interven-
tions such as insecticide treated bed nets and indoor residual spray.
As a result, many countries/regions are planning or have already
committed to eliminating malaria. In these areas the malaria
surveillance programs that generate information on malaria cases,
burden and transmission trends need to be strengthened and
extended to include case and foci investigations [2]. These focused
investigations play a pivotal role in informing malaria elimination
action plans and directing resources.
The effectiveness of malaria surveillance depends on the
performance of surveillance tools. Light microscopy (LM) has
been the main surveillance tool over the past decades. LM
provides important epidemiological information such as malaria
incidence rates, burden and relative species composition. Howev-
er, since the introduction of molecular based diagnostics, e.g.
polymerase chain reaction (PCR) in the 1990s, there has been
increased reporting of malaria infections in communities which are
detected by PCR, but not by LM. These reports demonstrate
LM’s limitation in detecting infections with low parasite densities;
levels well below the threshold for symptomatic malaria, but of
sufficient density to enable transmission of parasites to mosquitoes
[3,4]. Therefore, it is important to understand the epidemiology of
these sub-microscopic (SM) malaria infections in different settings
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and their role in maintaining malaria transmission, particularly in
the context of elimination strategies.
SM P. falciparum infections are well documented. A systematic
review and meta-analysis of P. falciparum LM and PCR
prevalence data revealed that on average, the prevalence of LM
was only 50.8% of that measured by PCR [5]. This suggests that
half of all detected P. falciparum infections were SM. The meta-
analysis revealed that the SM P. falciparum is more common in
adults, in areas with low transmission intensities and in chronic
infections [6]. Based on findings of earlier experimental studies,
Okell and colleagues estimated that SM P. falciparum contributes
between 20% and 50% of human to mosquito transmission in
areas with low and very low transmission intensity [6]. This has
great implications for malaria control and elimination programs
because SM P. falciparum infections cannot be readily detected by
diagnostic tools commonly used for case management or field
surveillance (such as LM and rapid diagnostic tests, RDTs) and
these undetected large reservoirs of SM P. falciparum can
maintain low level of transmission and seed outbreaks [7].
In contrast to P. falciparum, the prevalence and distribution of
SM P. vivax has not been systematically analysed despite
increasing reports of asymptomatic and SM P. vivax. This is a
major gap in moving forward with malaria elimination in certain
regions since it is likely that the epidemiology of SM P. vivax is
different to that of P. falciparum due to several unique biological
features of P. vivax. For example, parasite invasion of Duffy
positive reticulocytes is thought to contribute to the observed
overall lower parasite densities in P. vivax infections compared to
P. falciparum infections, thus heightening the theoretical likeli-
hood of having SM infections. Other features such as relapses may
affect the speed at which host immunity develops, which in turn
may affect parasite density. Mature gametocytes are present earlier
in P. vivax infections meaning they can infect mosquitoes at an
early stage of infection, with SM P. vivax gametocytes shown to be
able to successfully infect mosquitoes [8,9]. Dormant P. vivax
parasite stages in the liver (hypnozoites) that can activate at
variable periodicity depending on geographical region [10], means
that untreated SM infections will continue to relapse in the future
with the potential to continue transmission during each relapse.
Therefore, SM P. vivax poses a major challenge to malaria control
and elimination programs in areas where P. vivax is endemic.
In this study we reviewed published literature and analysed the
prevalence and relative proportion of SM P. vivax infections
across different transmission settings. We also investigated factors
associated with the occurrence of SM P. vivax infections. These
findings can support the reorientation of malaria control
programmes towards elimination of P. vivax.
Methods
Literature search
A literature search was conducted in PubMed using the search
terms ‘‘vivax, PCR, survey’’ in Jan 2014. These initial publications
(excluding 3 non-English papers) were then carefully reviewed and
selected according to the following inclusion criteria: 1) Data were
collected either from cross-sectional surveys of a population or a
representative subset of population at one point in time or from
screening studies of clinical malaria suspects, 2) Data include
separate microscopy and PCR-based results for P. vivax in the
same setting (RDT results were not considered), and 3) At least
one P. vivax infection was detected by either PCR or LM.
Data analysis
When results of multiple surveys were reported in a single
paper, either in different locations or in different season, data from
these surveys were combined if the authors did not report a
significant difference in prevalence between different locations or
seasons. However, if prevalence was reported to be significantly
different between locations or seasons by the authors each survey
was included separately, unless 1) the number of samples in each
location/season was ,50 and 2) there were no data provided for
each individual location/season.
Terminology
1.Microscopy method refers to detection of Plasmodium spp.
using light microscopy (LM) examination of thick and thin
blood smears following the WHO recommended protocol.
2.PCR method refers to detection of Plasmodium spp. by
amplification of any parasite gene using any PCR-based
technology, including conventional single round, multiplex,
nested, semi-nested PCR, real time quantitative PCR and
ligase detection reaction-fluorescent microsphere assay (LDR-
FMA).
3.Parasite prevalence determined by LM and PCR. This was
calculated as: total number of positive samples/total number of
samples examined6100%.
4.Prevalence of sub-microscopic (SM) infections. The SM
prevalence was calculated as: PCR prevalence – LM
prevalence. In surveys where LM prevalence was higher than
PCR prevalence, the prevalence of SM is considered as 0.
5.Relative proportion of sub-microscopic (SM) infections. This
was calculated as: SM prevalence/PCR prevalence6100%.
Statistical tests. Paired comparisons of LM and PCR, and
P. falciparum and P. vivax SM prevalence or SM proportion for
all sites were tested using Wilcoxon matched pairs signed rank test
(GraphPad Prism). Comparisons of LM, PCR and SM prevalence
or relative SM proportions between different age groups and
laboratory methods were performed using the Mann Whitney test.
Author Summary
Light microscopy (LM) has been the mainstay of malaria
diagnosis for case management and surveillance. The
introduction of molecular based diagnostics such as
polymerase chain reaction (PCR) in the 1990s resulted in
increased reporting of Plasmodium infections in commu-
nities compared to LM, indicating that sub-microscopic
(SM) Plasmodium infections are endemic in a variety of
different settings. The prevalence and transmission poten-
tial of SM P. falciparum was reviewed; however, informa-
tion on the prevalence and distribution of SM P. vivax in
different settings is not available. In this article, the authors
analysed LM and PCR results described in 38 publications
(44 studies), and revealed that SM P. vivax is highly
prevalent across different geographic areas with varying
transmission intensities. On average, these infections made
up 67% of P. vivax infections detected by PCR in cross-
sectional surveys, and were relatively more prevalent in
areas where malaria was under control and moving
towards elimination. By contrast, SM P. vivax is not
prevalent in clinical malaria suspects. These findings
highlight that for detection of clinical malaria LM and
rapid diagnostic tests (RDTs) are adequate, however, to
detect very low density infections that are largely
asymptomatic but still contribute to transmission, more
sensitive diagnostic tools are needed.
Sub-microscopic P. vivax Infections
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Regression analysis. The relationship between LM and
PCR prevalence was assessed using linear regression of the log10
transformed values. Log transformed values were used to resolve
heteroscedasticity. The relationship between LM prevalence and
proportion of SM infections was analysed using a generalized
linear model with a gamma distribution and log link function.
Results
Search outcome and data grouping
The PubMed search produced a list of 139 publications, of
which 38 met the inclusion criteria. Twenty five publications
[11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,
32,33,34,35] reported findings of 31 cross-sectional surveys of
different populations (including 29 cross-sectional surveys, one
reactive case investigation and one cohort study) that were
conducted by household or village based or random sampling.
The remaining 13 publications [18,36,37,38,39,40,41,42,43,44,
45,46,47] reported findings of fever/or clinically suspected
malaria patient screening. LM and PCR results reported in
these two groups of publications were analysed separately. The
location, year and references of these studies are summarised in
Table 1.
Prevalence of P. vivax and P. falciparum infections in
communities
The 31 cross-sectional community surveys were conducted in 12
countries (Table 1). Twenty eight of these surveys were conducted
between 1996 and 2010. Survey year was not described for the
remaining three surveys (Table 1). The number of samples tested
by PCR in each survey ranged from 98 to 3316 (median= 337,
interquartile range: 252 to 1269). The LM prevalence of P. vivax
ranged from 0.0% to 44.3% in geographically different settings,
while the corresponding PCR prevalence for P. vivax in these
same settings ranged from 0.2% to 59.5%. Overall across all sites,
the PCR prevalence of P. vivax was significantly higher than that
of LM (Wilcoxon matched-pairs signed rank test, P,0.0001,
Fig. 1), i.e. PCR detected a significantly higher number of P. vivax
infections than LM.
The prevalence of sympatric P. falciparum, including P.
falciparum in mixed species infections, was also analysed for 30
of the 31 surveys as a comparison. Prevalence of P. falciparum
determined by LM ranged from 0.0 to 40.4% while PCR
prevalence of P. falciparum PCR ranged from 0.0 to 81.5%.
Similar to P. vivax, the overall prevalence of P. falciparum
determined by PCR was significantly higher than that of LM
(Wilcoxon matched-pairs signed rank test, P,0.0001, Fig. 2).
Prevalence and relative proportion of SM P. vivax and P.
falciparum infections
The prevalence of SM P. vivax in the 31 community surveys
analysed ranged from 0.2 to 48.6% (Fig. 1). The relative
proportion of P. vivax not detected by LM (i.e. SM infections)
ranged from 1.5% to 100.0%, with a mean of 69.5% (Fig. 3). The
prevalence of SM P. falciparum ranged from 0.0% to 61.3%,
constituting, on average, 55.7% of P. falciparum infections (range
0.0% to 100.0%, Fig. 4).
The prevalence of SM P. vivax in these communities was not
significantly different to that of SM P. falciparum (Wilcoxon
matched-pairs signed rank test, P = 0.78, Fig. 5A). However, the
average relative proportion of SM was significantly higher in P.
vivax infections compared to P. falciparum in the same study
(Wilcoxon matched-pairs signed rank test, Median difference
= 5.2%, P=0.045, Fig. 5B).
Relationships between LM and PCR determined P. vivax
prevalence
A positive relationship between LM and PCR determined P.
vivax prevalence was observed (Fig. 6). LM P. vivax prevalence
was a significant factor for predicting PCR P. vivax prevalence in
community surveys (P,0.001, R2= 0.675). The fitted regression
equation is: log (PCR P. vivax prevalence) = 0.5966 log (LM P.
vivax prevalence) – 0.003. Thus, PCR detectable P. vivax
prevalence can be estimated based on LM P. vivax prevalence
for community surveys using quality LM and PCR with similar
sensitivities to those reported in the studies described here.
Relationship between LM and relative proportion of SM
P. vivax
A negative relationship between LM P. vivax prevalence and
proportion of SM P. vivax infections was identified (Fig. 7), with
LM P. vivax prevalence identified as a significant factor for
predicting the proportion of samples that are PCR positive/LM
negative (SM) in cross-sectional surveys where the LM P. vivax
prevalence is less than 45% (P,0.001, Deviance = 7.32, df = 29).
The regression equation describing this relationship is: proportion
SM P. vivax = exp (20.162–4.1636 LM P. vivax prevalence).
The negative relationship observed remains when a furthest outlier
was removed from the analysis.
Pathogenesis of SM P. vivax
The pathogenesis of SM could be indicated by the percentage of
infected individuals having malaria related symptoms at the time
of the survey. Malaria symptoms include acute symptoms normally
represented by fever, and chronic symptoms represented by
anaemia. Data on the proportion of symptomatic P. vivax mono
infections in PCR positive/LM negative subjects could only be
extracted from six studies [16,22,25,26,27,35], all of which were
conducted in areas with relatively low transmission (LM P. vivax
prevalence ranged 0.01% to 4.79%). The proportion of individuals
with symptoms ranged from 0.0% to 11.4%, averaging 2.8%. This
means that between 88.6 and 100.0% (average 97.1%) of
individuals with SM P. vivax were asymptomatic. To ascertain
whether these asymptomatic SM carriers will become symptom-
atic some time later, one study followed 25 LM negative/PCR
positive subjects in South America for two months and found they
remained asymptomatic over the 2 month duration [26].
The relationship between SM P. vivax and anaemia was
investigated by Ladeia-Andrade et al. [23] in Brazil using two-level
logistic regression models. After excluding LM positive subjects,
and controlling for covariates such as age and sex, they concluded
that the presence of SM P. vivax was a significant predictor of
anaemia (OR=1.92; 95% CI:1.14–3.23; P = 0.015).
Factors contributing to the occurrence of SM infections
1.Anti-parasite antibodies. Antibodies against P. vivax are a
marker of host immunity developed during previous infections.
Four cross-sectional surveys [22,25,26,28] included a serolog-
ical investigation of anti-P. vivax antibodies using ELISA or
IFA in parallel with LM and PCR. However, only two studies
compared serological and PCR results. Versiani et al [26]
observed that PCR positive/LM negative subjects were 2.45
fold more likely to have anti-PvMSP1 antibodies than PCR
negative/LM negative subjects in Amazonas State of Brazil,
and that the PCR positive/LM negative group had signifi-
cantly higher titres of anti-PvMSP1 antibodies than the PCR
negative/LM negative group [26]. Increased presence of anti-
PvMSP1 antibodies was also noted for PCR positive/LM
Sub-microscopic P. vivax Infections
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Table 1. Summary of location, year and references of the selected surveys.
Region Country - reference No Area Year of survey Reference
Cross-sectional surveys
Africa Angola-11 Caxito, Mabubas, Ucua 2010 [11]
ASIA Bangladesh-12a Bandarban district (4 sub-districts) 2007–2008 [12]
ASIA Bangladesh-12b Bandarban district (3 sub-districts) 2007 [12]
ASIA Cambodia-13 Rattanakiri 2001 [13]
ASIA Cambodia-14a Rattanakiri 2001 [14]
ASIA Cambodia-14b Rattanakiri 2001 [14]
ASIA Indonesia-15 Flories Island 2008 [15]
ASIA Indonesia-16 Aceh 2010 [16]
ASIA Lao-17 Xepon district 2006 [17]
ASIA Malaysia-18 Sabah NR [18]
ASIA Thailand-19 Kanchanaburi, Pathumthani, Nakornpathom 2009 [19]
South America Brazil-20a Ji-Parana 2000 [20]
South America Brazil-20b Portuchuelo 1998 [20]
South America Brazil-20c Portuchuelo 1999 [20]
South America Brazil-21 Para State NR [21]
South America Brazil-22 Amazon state NR [22]
South America Brazil-23a Riverine-ABD 2002–2003 [23]
South America Brazil-23b Riverine-CE 2002–2004 [23]
South America Brazil-24 Porto Velho, Rondonia 2004–2007 [24]
South America Brazil-25 Espirito Santo 2001 [25]
South America Brazil-26 Amazonas State 2008 [26]
South America Peru-27 Iquitos 1999 [27]
South America Peru-28 Bellavista 2010 [28]
South America Venezuela-29* Amazonas and Sucre state NR [29]
South Pacific PNG-30 East Sepik 1996 [30]
South Pacific PNG-31 North of Madang 2000 [31]
South Pacific PNG-32a Central Sepik, Sepik River 2005 [32]
South Pacific PNG-32b Central Sepik, Foot hills 2005 [32]
South Pacific PNG-33 Maprik District 2006 [33]
South Pacific PNG-34 Wosera 2001–2003 [34]
South Pacific Solomon Is-35** Temotu 2008 [35]
Screening clinical malaria suspects
Africa Mauritania-36 Nouakchott 2007 [36]
Africa Mauritania-37 Nouakchott 2009 [37]
Africa Sudan-38 Refugee camps 1997 [38]
Asia India-39 Didori and Shivpuri 2009 [39]
Asia Malaysia-18 Hospitals NR [18]
Asia Myanmar-40 Yangon and Mandalay 2000 [40]
Asia Pakistan-41 Khyber Pakhtunkhwa, Sindh, Balochistan, Punjab, Islamabad 2011 [41]
Asia Thailand-42 Northern Thailand NR [42]
Asia Thailand-43 Umpang 2010 [43]
Europe Italy-44 Parma 2000–2007 [44]
Europe Italy-45 Parma 2005–2006 [45]
Europe Spain-46 Hospitals 1997–1998 [46]
South America Brazil-47 Amazone 2006–2007 [47]
NR: not reported
*223/295 samples were randomly selected
**PCR rates are estimates based on PCR results of a random sample set.
doi:10.1371/journal.pntd.0003413.t001
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positive subjects (compared to subjects with no evidence of P.
vivax infection), however there were too few cases positive by
both PCR and LM (n= 15) to achieve statistical significance, or
compare between SM and patent infections. A second study
conducted in Bellavista, Peru observed that PCR positivity was
significantly associated with the presence of anti-PvMSP1
antibodies [28], however no comparison was made between
SM and patent infections.
2.Age. In many malaria endemic settings, the adolescent
population has higher proportions of asymptomatic and low
density Plasmodium infections than young children due to the
development of clinical immunity after repeated exposure to P.
vivax parasites. Therefore, age is a surrogate marker for
acquired clinical immunity. Fifteen of the 25 publications (21 of
the 31 surveys) described prevalence of P. vivax infection in
different age groups, but only 12 publications (16 surveys)
analysed the relationships between P. vivax LM or PCR
prevalence and age. Seven publications (eight surveys) found no
significant association between the relative proportion of SM
P. vivax infection and host age [14,15,17,22,27,28,30], while
five publications (eight surveys) reported that the relative
proport ion of SM P. vivax increased with age
[12,23,31,32,34]. Neither the LM nor the PCR P. vivax
prevalence was significantly different between the studies that
did and did not find an association with age (Mann Whitney
test, P.0.05).
3.Microscopy QA and DNA extraction method for PCR.
The prevalence and relative proportion of SM P. vivax could
vary because of differences in quality of microscopy and PCR.
Only one [35] of the 25 publications (1 of the 31 surveys) stated
the competency levels of microscopists according to the WHO
accredited malaria microscopy competency assessment. Eleven
publications (15 surveys) described the microscopists as experts,
experienced, highly skilled or well-trained but did not provide
information on qualifications. Fifteen of the 31 surveys reported
some form of quality assurance (QA) of the microscopy including
two independent microscopists reading and/or an expert referee
to confirm positives, discordant slides and random selection of
negatives, as well as PCR positive results. However, the presence
or absence of a description for performing microscopy QA did
not affect the average prevalence of SM (Mann Whitney test,
P = 0.2447) or the average proportion of SM P. vivax (Mann
Whitney test, P = 0.1626).
While quality of microscopy largely depends on the competency
of microscopists, quality of PCR can be particularly influenced
by the type and volume of blood used to extract DNA. All
surveys described the type of blood and DNA extraction method
used for PCR analysis. Fourteen surveys used blood from filter
paper while 17 surveys used whole blood (primarily.150 mL) for
DNA extraction. The average LM prevalence of P. vivax was
not significantly different between these two methods of DNA
extraction (Mann Whitney test, P = 0.161). However, the
average prevalence of SM P. vivax in community surveys
determined by PCR using whole blood was significantly higher
than that using blood from filter papers (Mann Whitney test,
P = 0.004).
4.Fever and drug use. Antimalarial drug use could also affect
parasite density at the time of survey and thereby increase the
prevalence and relative proportion of SM P. vivax. Only one
survey reported that recent antimalarial treatment (,4 weeks
prior to survey) was associated with a significant increase in risk
of having SM P. vivax infection [33].
Fig. 1. Prevalence of LM (light microscopy, blue bar) and SM (sub-microscopy, red bar) P. vivax in cross-sectional surveys. The total
height of each bar (blue + red) represents the PCR prevalence. Countries where data were collected and their corresponding references (detailed in
Table 1) are shown on the x-axis.
doi:10.1371/journal.pntd.0003413.g001
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Prevalence of SM P. vivax infections in surveys among
clinical malaria suspects and their proportions in
different settings
In 13 surveys of clinical malaria suspects conducted in different
transmission settings (1997–2010), the prevalence of P. vivax
infections determined by LM varied widely from 0.7% to 86.0% of
the patients. Although PCR detected more P. vivax infections in
some studies, overall it did not have a significantly higher prevalence
than LM in fever patients (Wilcoxon matched-pairs signed rank test,
P = 0.278, Fig. 8). In these same surveys, the LM P. falciparum
prevalence rates ranged from 1.0% to 54.2% while PCR prevalence
rates ranged from 1.0% to 46.9%. Similar to P. vivax, PCR did not
detect a significantly higher number ofP. falciparum infections than
LM in these patients (Wilcoxon matched-pairs signed rank test,
P = 0.123, Fig. 9). This suggests that amongst symptomatic patient
populations SM P. vivax and P. falciparum are not prevalent.
Discussion
Sub-microscopic malaria infections have been increasingly
reported in malaria endemic areas, especially in places where
malaria transmission intensities are relatively low and where
malaria elimination is being targeted. In this paper, published
articles from varying transmission intensities were reviewed and
data extracted for secondary analysis with the purpose of
providing an overview of SM P. vivax malaria in different settings
including its prevalence and relative proportion of all detectable P.
vivax infections, and relationship with LM prevalence, as well as
consideration of the factors contributing to SM P. vivax.
The 31 cross-sectional surveys reviewed were conducted in
areas where LM P. vivax prevalence ranged from 0 to 44%. Since
entomological inoculation rate (EIR) was not reported in these
surveys, we used LM P. vivax prevalence as an indicator of
transmission intensity in each setting. One of the advantages of
using LM prevalence instead of PCR prevalence is that LM
prevalence has been used as a measure of transmission intensity in
endemic countries for the past century. Our analysis showed that
the PCR P. vivax prevalence was significantly higher than that
LM P. vivax prevalence in these surveys, demonstrating the
presence of a sub-population carrying SM P. vivax across all
transmission settings. The prevalence of SM P. vivax infections
ranged from 0.2% to 48.6%. SM P. vivax constitutes between
1.5% and 100% of all P. vivax infections detected by PCR
(average 69.5%) in these settings, and this proportion is
significantly higher than that of the sympatric P. falciparum
infections. This suggests that without PCR or other comparably
sensitive methods, an average of 69% of P. vivax infections would
be undetected hence antimalarial treatment will usually not be
sought. This results in a potentially large group of people carrying
parasites that have the potential to transmit P. vivax [8,9] and
maintain the transmission cycle. Furthermore, the majority of
these people are asymptomatic and may remain so for months
[26].
Similar to the epidemiology of SM P. falciparum reported by
Okell et al.[6], a negative relationship was identified between the
relative proportion of SM P. vivax and LM P. vivax prevalence in
31 cross-sectional surveys. This suggests that a relatively larger
proportion of P. vivax infections are SM in areas with low
transmission intensity compared to areas with high transmission
Fig. 2. Prevalence of LM (light microscopy, blue bar) and SM (sub-microscopy, red bar) of sympatric P. falciparum in cross-sectional
surveys. Total height of each bar (blue + red) represents the PCR prevalence. Countries where data were collected and their corresponding
references (detailed in Table 1) are shown on the x-axis.
doi:10.1371/journal.pntd.0003413.g002
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intensity, although SM P. vivax is prevalent in both type of
settings. Hence, SM P. vivax poses more challenges to malaria
control programs in areas where transmission intensities are
already low and are progressing toward elimination.
Many factors can contribute to the occurrence and level of SM
P. vivax. These include technical, parasite and host factors. From
a technical point of view, the quality of microscopy is an important
factor that can contribute to the level of LM P. vivax, and thus
SM P. vivax. The prevalence and relative proportion of SM P.
vivax would increase if the microscopist is relatively poor at
detecting parasites, or decrease if there are false positive results (eg
cell debris wrongly classified as a parasite). The correct speciation
of parasites is also important in areas with both P. falciparum and
P. vivax. This is a special concern since quality of field microscopy
has been shown to be highly variable [48,49,50,51,52,53,54].
Interestingly, the description of microscopy QA was not found to
be associated with the prevalence or relative proportion of SM P.
vivax in the 31 cross-sectional surveys reviewed. This indicates
that the quality of microscopy of these surveys was comparable
between studies, irrespective of whether QA was reported or not.
Quality of PCR is also an important determinant for the level of
SM P. vivax. It might be expected that a sensitive PCR would
detect more SM P. vivax than a less sensitive PCR in a field
survey. The PCR sensitivity is largely determined by the quality
and amount of parasite DNA and by copy number of the target
gene. Of the 31 cross-sectional surveys, 29 (93.5%) used a PCR-
based assay targeting the parasite 18sRNA gene. Therefore, the
sensitivity of these PCR methods would most likely be affected by
the number of parasites added in each assay which is determined
by the volume of blood used for DNA extraction and the
concentration of parasite DNA. Seventeen of the 31 cross-sectional
surveys used .150 mL of whole blood while 14 surveys used dried
blood spot on filter paper which usually contain 5-20 mL of blood.
As expected, the surveys using whole blood produced a
significantly higher average prevalence of SM P. vivax compared
to the surveys using filter paper blood. Although the final volume
of DNA elusion could not be assessed, this difference is likely due
to the higher number of parasites present in the larger volume of
whole blood, resulting in more parasite DNA being added into
each assay. This finding suggests that while filter paper helps to
preserve blood in field conditions and assists with transportation of
samples, the method is less sensitive than whole blood in detecting
SM P. vivax. In order to maximize PCR sensitivity in detecting
SM parasite infections, .150 mL of whole blood should be used
when possible.
Parasite factors influencing SM P. vivax may include the
growth characteristics and virulence of parasite strains, as well as
genetic diversity, susceptibility to antimalarial drugs and related-
ness of parasite strains. While the former, which is difficult to study
in the field, may directly affect the parasite density, the latter could
indirectly affect the parasite density through effective host
immunity. For example, homogeneity of parasite population, i.e.
lack of genetic diversity, is often reported in areas with low
transmission intensity, such as Peru and South American countries
[55,56,57]. This limited parasite genetic diversity could speed up
the development of acquired immunity in a host population, which
in turn could reduce parasite density in the host resulting in a
higher proportion of SM infections. However, parasite diversity
was not reported as part of any of the surveys reviewed. Recently,
Gray et al [58] reported genetic diversity and parasite relatedness
Fig. 3. Relative proportion of SM (sub-microscopy) P. vivax in cross-sectional surveys. Countries where data were collected and their
corresponding references (detailed in Table 1) are shown on the x-axis.
doi:10.1371/journal.pntd.0003413.g003
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in Temotu, Solomon Islands as a follow up of the baseline survey
[35]. In the baseline survey 75% of LM positive P. vivax infections
had parasite densities below 100/mL with a further 44% of P.
vivax infections being SM P. vivax; 94% of all P. vivax infections
were asymptomatic at the baseline survey. However, genetic
diversity of P. vivax population was very high and parasite
Fig. 4. Relative proportion of sympatric SM (sub-microscopy) P. falciparum in cross-sectional surveys. Countries where data were
collected and their corresponding references (detailed in Table 1) are shown on the x-axis.
doi:10.1371/journal.pntd.0003413.g004
Fig. 5. A) Comparison of SM (sub-microscopy) P. vivax and SM (sub-microscopy) P. falciparum prevalence (mean with 95% CI) in 31
cross-sectional surveys. B) Comparison of relative proportions of SM (sub-microscopy) P. vivax and P. falciparum (mean with 95% CI) in 31 cross-
sectional surveys.
doi:10.1371/journal.pntd.0003413.g005
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haplotypes were not highly related [58]. This suggests that genetic
diversity of P. vivax was not a major contributor to the high
prevalence of SM P. vivax in this setting.
Host factors including non-specific immune responses, immu-
nity status and human genetics could greatly impact parasite
density, and hence the prevalence and proportion of SM P. vivax.
Firstly, the non-specific immune response commonly associated
with febrile illness has been hypothesized to directly reduce
parasite density [59,60] and any resultant antimalarial treatment
can rapidly eliminate parasites. The effect of febrile illness and
antimalarial treatment on SM P. vivax was investigated in one of
the 32 cross-sectional surveys reviewed [33]. Lin et al. reported
that fever episodes in the two weeks prior to sample collection, and
antimalarial treatment 4 weeks prior, were associated with a
significant reduction in risk of being detected by LM or PCR-
based method [33]. Therefore, antimalarial treatment reduces
both LM and SM P. vivax infections.
Host immune status could also be a major determinant of SM P.
vivax. It has been reported that SM P. falciparum is more common
in adults compared to children [6]. However, this pattern was not
exactly repeated in P. vivax. Of the 16 surveys that analysed the
relationship of SM P. vivax with age, eight reported the relative
proportion of SM P. vivax was not associated with age, while the
other eight reported that the relative proportion of SM P. vivax
increased with age. This difference may be related to the transmission
intensities in study regions, however a comparison of the average LM
P. vivax prevalence between these two groups did not show a
significant difference. One other possibility may be difference in
geographical or host population; the group of surveys reporting no
association with age were mostly conducted in Southeast Asia and
South America, while those reporting an association included four
surveys conducted in PNG. The presence and quantity of anti-
PvMSP1 antibodies have also been associated with SM P. vivax in
two surveys conducted in South America [26][28]. This suggests that
serology may help detect SM P. vivax carriers.
Associations between other host factors such as polymorphisms
in Duffy antigen, haemoglobin or G6PD and SM P. vivax
Fig. 6. Relationship between LM (light microscopy) and PCR
determined P. vivax prevalence in 31 cross-sectional surveys.
doi:10.1371/journal.pntd.0003413.g006
Fig. 7. Relationship between LM (light microscopy) and SM (sub-microscopy) P. vivax prevalence in 31 cross-sectional surveys.
doi:10.1371/journal.pntd.0003413.g007
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infections were not investigated in any of the 31 cross-sectional
surveys reviewed. Further studies are required to ascertain the
contribution of host genetics to SM P. vivax infections.
Based on findings of six surveys, between 89% and 100%
(average 97.5%) of SM P. vivax infected subjects were asymp-
tomatic at the time of survey and it was not well documented
whether these people progressed to develop LM detectable
parasitemia at a later time. One study followed 25 LM-/PCR+
subjects and found them all asymptomatic after a 2 month follow
up [26]. If these individuals remain asymptomatic then they would
not be identified by either active or passive case detection based on
LM or RDTs with a similar sensitivity to LM.
Fig. 8. Prevalence of LM (light microscopy, blue bar) and SM (sub-microscopy, red bar) P. vivax in clinical malaria suspects. Total
height of the bar (blue + red) represents the PCR prevalence.
doi:10.1371/journal.pntd.0003413.g008
Fig. 9. Prevalence of LM (light microscopy, blue bar) and SM (sub-microscopy, red bar) P. falciparum in clinical malaria suspects. Total
height of bar (blue + red) represents PCR prevalence.
doi:10.1371/journal.pntd.0003413.g009
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Any individual infected with blood stage P. vivax, regardless of
the level of parasitemia, is likely carrying dormant hyponozoites in
the liver and is thus likely to relapse weeks to months after the
primary infection. Future relapses in these individuals can only be
limited by treatment that includes antimalarials (specifically,
primaquine) targeting the P. vivax hypnozoites. Therefore, to
prevent relapse WHO recommends that in low transmission areas
patients with P. vivax infection, who are not G6PD deficient,
receive treatment against both blood (such as chloroquine) and
hypnozoite (primaquine, 0.25 or 0.5mg/kg/day once a day for 14
days) stages [61]. However, SM P. vivax infections are not
detectable using LM or RDTs, as such these infected individuals
would not receive any anti-malarial therapy for P. vivax blood or
liver stages and thus continue to transmit P. vivax. The prevalence
of this undetectable and untreated SM P. vivax population creates
a major challenge to malaria control and elimination programs.
Strategies for detecting and treating infected cases (patent and
symptomatic infections) alone will unlikely interrupt transmission
because SM P. vivax infections and their future relapses will
continue to feed into transmission. Comparing to SM P.
falciparum, SM P. vivax infections represent a more important
transmission reservoir due to multiple relapses occurring over a
long period of time. To accelerate malaria elimination i.e. the
complete interruption of malaria transmission and total removal of
the disease burden of malaria such as anaemia, some form of mass
screening using PCR-based or comparably sensitive methods and
radical cure approach would be required to identify and treat all
SM P. vivax infected subjects. This strategy would be expected to
have more impact on P. vivax transmission than on P. falciparum
transmission because appropriate management of SM P. vivax
will not only stop transmission from current SM infections, but
also prevent future relapses and transmissions resulting from these
relapses. However, because the conventional PCR based assays
are expensive to implement and difficult to perform under field
conditions, mass screening will not be practical before more
sensitive and specific field deployable diagnostic tests become
available. Cost-effectiveness studies will be needed to properly
evaluate the options available for P. vivax elimination strategies
for different transmission settings. In the interim, the PCR
prevalence of P. vivax could be estimated based on the positive
relationship between PCR P. vivax prevalence and LM P. vivax
prevalence identified in this study. If the prevalence of PCR
positive P. vivax is much higher than that of LM, mass drug
administration may be an option for elimination but it also has its
operational challenges, risks and potential limitations [62].
In contrast to cross-sectional surveys, SM P. vivax was much
less prevalent in clinical malaria suspects. Overall, the PCR
prevalence for P. vivax or P. falciparum was not significantly
higher than that of LM in 13 surveys of febrile patients. This could
be due to relatively high parasite density in symptomatic patients.
This re-emphasizes that quality LM and RDTs are adequate tools
for case management of both P. vivax and P. falciparum patients.
In summary, SM P. vivax is prevalent across different
geographic areas with varying transmission intensities constituting,
on average, 69.5% of all P. vivax infections. The relative
proportion of SM P. vivax is significantly higher than that of
the sympatric P. falciparum in these settings and is higher in areas
with relatively low transmission intensity. These SM P. vivax
infections not only have negative health impact on the infected
individual, but will also contribute to P. vivax transmission both
from the current infection and subsequent relapses, and thus
present a major challenge for malaria elimination programs. This
review seeks to provide malaria control and elimination programs
with estimates of the prevalence and proportion of SM P. vivax
infections in their settings, and to highlight the importance of
developing diagnostic tools for detecting SM P. vivax infections in
order to support elimination strategies. Strategies for tackling both
patent and SM P. vivax are critical for eliminating P. vivax.
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